ENTITY
Pharmaessentia Corp

Pharmaessentia Corp (6446 TT)

53
Analysis
Health CareTaiwan
PharmaEssentia Corporation develops and distributes therapeutic products for treatment in human disease. The Company develops drugs to treat hepatitis, chronic myeloid leukemia (CML), essential thrombocythemia (ET), myeloid fibrosis (MF), polycythemia vera (PV), hepatitis and cancer.
more
bullishRakuten Bank
23 Apr 2023 07:25

ECM Weekly (23rd Apr 2023) - Rakuten Bank, Merdeka, ZJLD, Mankind, Lalatech, IMotion, Anta, KIT

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
418 Views
Share
bullishRakuten Bank
16 Apr 2023 10:00

ECM Weekly (16th Apr 2023) - Rakuten Bank, Harita Nickel, Merdeka Battery, ZJLD, Adicon, Supcon

Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.

Logo
354 Views
Share
13 Apr 2023 19:39

PharmaEssentia GDS Issuance - Strong Revenue Growth and Narrowing Losses

Pharmaessentia Corp (6446 TT) aims to raise around US$412m (TWD12.6bn) via a GDS issuance. In this note, we will talk about the deal dynamics and...

Logo
Ethan Aw
952 Views
Share
15 Feb 2023 15:24

Pharmaessentia Corp (6446 TT): Besremi Starts 2023 on Strong Note; Geography Expansion Continues

Pharmaessentia reported 259% YoY revenue growth in January, driven by strong uptake of Besremi in US. The drug is expected to receive approvals in...

Logo
550 Views
Share
23 Dec 2022 14:05

2022 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe

From my coverage universe, two Taiwanese stocks generated 59% and 71% returns in nearly six months. New product launch and geography expansion are...

Logo
714 Views
Share
x